Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NMS-03305293 + Temozolomide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NMS-03305293 | NMS03305293|NMS 03305293 | PARP Inhibitor (Pan) 31 | NMS-03305293 inhibits PARP, potentially resulting in decreased repair of DNA damage and increased tumor cell apoptosis (NCI Thesaurus). | |
Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Recruiting | USA | NLD | ITA | CHE | 0 |